A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Poly ICLC (Primary)
- Indications Brain cancer
- Focus Adverse reactions; Pharmacodynamics
- 04 Oct 2017 Planned End Date changed from 31 Mar 2022 to 31 May 2022.
- 04 Oct 2017 Planned primary completion date changed from 30 Apr 2019 to 30 Jun 2019.
- 04 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 31 Dec 2017.